Curis raises $18.6M, pivots to PCNSL/CLL as Erivedge sale ends revenue; faces Nasdaq delisting

Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 6, 2025 · ~2 min read

Key Changes

• high

  Company received Nasdaq delisting notice April 27, 2026 after stock traded below $1.00 for 30 days; requested hearing May 4 to stay delisting, but no assurance appeal will succeed. Delisting would severely impair liquidity and capital access.

  Risk Factors verify on EDGAR →
• high

  January 2026 PIPE financing raised $18.6M through preferred stock and warrants that converted to 26.2M common shares in March. Despite this capital raise, cash fell from $20.3M to $15.0M year-over-year as quarterly burn reached $9.0M.

  MD&A: Liquidity verify on EDGAR →
• high

  Erivedge royalty rights sold to Oberland in November 2025 for $2.5M upfront, eliminating company's only revenue stream. Q1 2026 revenue was zero versus $2.4M prior year; company now entirely dependent on raising capital.

  MD&A: Erivedge Sale verify on EDGAR →